Program Title

Dr. Msaouel urges cancer patients to be cautious to avoid infection with COVID-19, especially due to increased impact complications that may occur. Monitor for these signs and symptoms to get in early communication with your oncology team.

Dr. Pavlos Msaouel breaks down the steps patients can take to detect Renal Medullary Carcinoma (RMC) early. First, patients must know whether they carry the sickle cell trait or not. Second, if blood is present in the urine, going to see a doctor immediately for further testing. Third, if you are indeed diagnosed with RMC, it’s important to contact physicians who are dedicated to treating this cancer. Lastly, get in touch with patient advocates and communities so you are not alone.

Dr. Pavlos Msaouel of The University of Texas MD Anderson Cancer Center discusses whether patients with sickle cell disease or who carry the sickle cell trait may be at increased risk for renal medullary carcinoma (RMC).

Dr. Msaouel answers questions from the Sickle Cell community. If the disease or trait evolved as a defense against Malaria, does the reported effectiveness of anti-malaria drugs like hydroxychloroquine (Plaquenil) mean that sickle cell patients have natural resistance to the novel coronavirus, COVID-19?

Dr. Msaouel tackles the question of how providers can combat inequities in the care of Renal Medullary Carcinoma (RMC) patients. Patients, especially young African Americans, go undiagnosed because of inadequate awareness and screening of RMC. Providers need to raise more awareness about RMC in the US and globally.

Respected oncologist, Dr. Pavlos Msaouel of The University of Texas MD Anderson Cancer Center, explains what renal medullary carcinoma (RMC) is and what symptoms typically present at diagnosis.

Dr. Pavlos Msaouel shares how patients can effectively self -advocate if diagnosed with Renal Medullary Carcinoma (RMC). First, a patient must know that treatment for RMC differs from other kidney cancers, so it is necessary to seek experts familiar with the particulars of RMC. Second, patients should reach out to communities who participate in RMC clinical trials.

Dr. Pavlos Msaouel discusses disparities that exist for patients with Renal Medullary Carcinoma (RMC). Young African Americans as well as Nigerians on a global scale are underdiagnosed due to lack of resources such as health insurance and research reports.